Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FGEN logo FGEN
Upturn stock ratingUpturn stock rating
FGEN logo

FibroGen Inc (FGEN)

Upturn stock ratingUpturn stock rating
$11.13
Last Close (24-hour delay)
Profit since last BUY32.97%
upturn advisory
Consider higher Upturn Star rating
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: FGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $43

1 Year Target Price $43

Analysts Price Target For last 52 week
$43 Target price
52w Low $4.5
Current$11.13
52w High $21.94

Analysis of Past Performance

Type Stock
Historic Profit 1.32%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 45.01M USD
Price to earnings Ratio -
1Y Target Price 43
Price to earnings Ratio -
1Y Target Price 43
Volume (30-day avg) 2
Beta 0.77
52 Weeks Range 4.50 - 21.94
Updated Date 08/29/2025
52 Weeks Range 4.50 - 21.94
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -21.61

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.09
Actual -1.88

Profitability

Profit Margin -28.12%
Operating Margin (TTM) -864.91%

Management Effectiveness

Return on Assets (TTM) -16.4%
Return on Equity (TTM) -1015.79%

Valuation

Trailing PE -
Forward PE 61.35
Enterprise Value 95374595
Price to Sales(TTM) 6.13
Enterprise Value 95374595
Price to Sales(TTM) 6.13
Enterprise Value to Revenue 12.63
Enterprise Value to EBITDA -0.17
Shares Outstanding 4043900
Shares Floating 3623697
Shares Outstanding 4043900
Shares Floating 3623697
Percent Insiders 1.58
Percent Institutions 26.54

ai summary icon Upturn AI SWOT

FibroGen Inc

stock logo

Company Overview

overview logo History and Background

FibroGen, Inc. is a biopharmaceutical company founded in 1993. It focuses on the discovery, development, and commercialization of therapeutics to treat fibrosis, anemia, and cancer. A significant milestone was the approval and launch of roxadustat for anemia in various countries outside the U.S.

business area logo Core Business Areas

  • Pharmaceutical Development: FibroGen focuses on researching and developing novel therapeutics for unmet medical needs in fibrosis, anemia, and oncology.
  • Commercialization Partnerships: The company collaborates with pharmaceutical partners like AstraZeneca and Astellas to commercialize its products globally.

leadership logo Leadership and Structure

FibroGen is led by a management team with expertise in drug development and commercialization. The company's organizational structure includes research and development, clinical operations, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Roxadustat: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia associated with chronic kidney disease (CKD). While approved in Europe, China, Japan, and other regions, its approval in the U.S. has faced challenges. Competitors include erythropoiesis-stimulating agents (ESAs) like epoetin alfa (Amgen's Epogen/Procrit) and darbepoetin alfa (Amgen's Aranesp). Market share data varies by region and indication. Revenue varies based on partnerships and regional sales. No current market share number in the US.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for anemia treatments is mature but with growing demand for novel therapies.

Positioning

FibroGen is positioned as an innovator in the development of HIF-PH inhibitors for anemia. Its competitive advantage lies in its novel oral drug, roxadustat, which offers a convenient alternative to injectable ESAs.

Total Addressable Market (TAM)

The global anemia market is substantial and expected to grow. While a specific TAM isn't provided here, FibroGen aims to capture a significant share of the CKD-associated anemia market with roxadustat.

Upturn SWOT Analysis

Strengths

  • Novel HIF-PH inhibitor technology
  • Established partnerships with major pharmaceutical companies
  • Roxadustat approved in multiple regions

Weaknesses

  • Regulatory setbacks in the U.S.
  • Reliance on partnerships for commercialization
  • Limited product portfolio

Opportunities

  • Expansion into new indications for roxadustat
  • Development of new therapeutics in fibrosis and oncology
  • Potential for U.S. approval of roxadustat

Threats

  • Competition from existing anemia treatments (ESAs)
  • Regulatory hurdles and clinical trial risks
  • Patent expirations and generic competition

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • MRK
  • SNY

Competitive Landscape

FibroGen's advantage lies in its oral HIF-PH inhibitor technology, but it faces intense competition from established ESAs and biosimilars. A U.S. approval of roxadustat is vital to their competitive landscape.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by the development and commercialization of roxadustat outside the U.S.

Future Projections: Future growth depends on the success of roxadustat in existing markets, potential U.S. approval, and the development of new pipeline products. Analyst estimates vary based on these factors.

Recent Initiatives: Recent initiatives include efforts to address regulatory concerns in the U.S. and expand the development of pipeline assets.

Summary

FibroGen is a biopharmaceutical company with an innovative technology in HIF-PH inhibition. Roxadustat's approval in many regions is a success. However, regulatory challenges in the US remain an obstacle. Further pipeline success is crucial. Competition in the anemia market is intense, presenting both threats and opportunities for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Press releases
  • Financial News Sources

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Financial data needs to be dynamically gathered from financial news sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About FibroGen Inc

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 2014-11-14
CEO & Director Mr. Thane Wettig
Sector Healthcare
Industry Biotechnology
Full time employees 225
Full time employees 225

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.